MDTMDT
US • —
$78.23
P/E
20.99
PEG
6.77
FCF Yield
—
Rev Growth YoY
+8.4% YoY
Gross Margin
65.3%
Health Score
8/10
D/E Ratio
0.57
Confidence
LOW
Business Snapshot
Medtronic is a medical device company that develops and manufactures therapies for a range of conditions, including cardiac rhythm disorders, neurological diseases, and spinal conditions. The company operates in the concentrated medical technology market as a well-established incumbent with a broad product portfolio spanning multiple therapeutic areas. While Medtronic is a large-cap multinational firm, the exact market capitalisation and trailing twelve-month revenue figures are unavailable in this data set. A defining characteristic of the company is its entrenched distribution network and long-term relationships with healthcare providers, which create a meaningful competitive moat in the highly regulated medical device industry.
Financial Health
The company reports a gross margin of 65.3% and a net margin of 13.2%, indicates a moderately profitable business with decent pricing power within its market. Balance sheet leverage appears manageable with a debt-to-equity ratio of 0.57x, and near-term liquidity is healthy as reflected by a current ratio of 2.13x...
Risk Assessment
- EARNINGS QUALITY — Earnings growth of 3.1% lagged revenue growth of 8.4% by a wide margin, raising concerns about margin dilution.
- VALUATION DIVERGENCE — DCF fair value estimates were not available for this period, leaving a significant gap in fundamental valuation context.
- INSIDER ACTIVITY — Insiders have executed 2 sells versus 0 buys over the last 90 days, a net-selling pattern that can signal limited confidence at the top.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed....
The company reports a gross margin of 65.3% and a net margin of 13.2%, indicates a moderately profitable business with decent pricing power within its market. Balance sheet leverage appears manageable with a debt-to-equity ratio of 0.57x, and near-term liquidity is healthy as reflected by a current ratio of 2.13x. Return on equity stands at 9.8%, suggesting an adequate but not exceptional return on shareholder capital. Free cash flow and FCF yield data are not available for a full cash generation assessment. Overall, the financial profile points to a durable business with a conservative capital structure and margins that support reinvestment and a consistent dividend.
- EARNINGS QUALITY — Earnings growth of 3.1% lagged revenue growth of 8.4% by a wide margin, raising concerns about margin dilution. - VALUATION DIVERGENCE — DCF fair value estimates were not available for this period, leaving a significant gap in fundamental valuation context. - INSIDER ACTIVITY — Insiders have executed 2 sells versus 0 buys over the last 90 days, a net-selling pattern that can signal limited confidence at the top. - TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives